Who says you can’t have it all? The Broan InVent™ Series ventilation fans have a brand new look with the same superior performance. The revolutionary airtightness and easy installation the InVent Series is known for, is now available in over nine decorative designs. For the first time, homeowners don’t have to compromise between aesthetic and performance.
As the industry leader in residential ventilation, Broan-NuTone has a long history of developing products that provide superior indoor air quality. It is this reputation and commitment to innovation and quality that led Broan to enhance the revolutionary and easy to install InVent Series.
To view the multimedia release go to:
http://www.multivu.com/players/English/7951551-broan-nutone-invent-series/
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Decorated U.S. war veteran Romulo (Romy) Camargo starts his day like most of us. He wakes up, gets a drink of water, has some breakfast, brushes his teeth, and gets dressed. But for Camargo, whose injuries in Afghanistan left him paralyzed from the neck down, these morning routines require some assistance. And Toyota is learning how to help.
Thanks to Camargo, Toyota recently completed the first North American in-home trial of the Human Support Robot (HSR). The HSR is one of the “partner robots” Toyota is developing to assist people with everyday activities. Toyota is actively researching ways to apply advanced technologies to help people with limited mobility, including seniors or those who are disabled.
To view the multimedia release go to:
https://www.multivu.com/players/English/8053352-toyota-human-support-robot-mobility-disability/
Building on a successful campaign that helped hundreds of thousands of Americans learn their risk of developing type 2 diabetes through campaign messaging and an online risk test, the first-of-its-kind initiative to raise national awareness of prediabetes returns with an entertaining new approach. The new campaign, launching today, encourages viewers to take a one-minute prediabetes risk test to know where they stand and discover how they can decrease their risk of developing type 2 diabetes — and it does so with some adorable helpers.
More than one in three American adults has prediabetes — a serious health condition that often leads to type 2 diabetes and other significant health conditions like blindness, heart attack or stroke. According to newly released CDC data, however, nearly 90 percent of the 84 million people with prediabetes don’t know they have it and aren’t aware of the long-term risks to their health. Currently, about 30 million Americans are living with diabetes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8142351-ad-council-prediabetes/
The U.S. workforce is changing and, with it, so are the ways in which employees are being relocated for companies across the United States. Cartus Corporation, a leading provider of global relocation services, recently released its 2017 Domestic U.S. Relocation Policy and Practices Survey results, a report that examines the responses of 141 mobility managers representing more than 10 million employees. While the overall survey explores trends in how companies are supporting home sale for transferring employees, responding to a growing rental population, and developing intern programs, the primary finding is the identification of a changing pattern in employee relocation, in which an increasing demand for flexibility is translating into different types of work transfers.
To view the multimedia release go to:
https://www.multivu.com/players/English/8035752-new-cartus-survey-shows-employee-relocation-trends/
Stella Artois, part of the Anheuser-Busch family of brands, and Water.org today announced a call to action for all beer lovers who plan to watch this year’s Super Bowl, the most highly watched event of the year. By stocking up on Stella Artois beer for the big game and beyond, people across the country can help provide access to clean water for those in the developing world. More than 663 million people are impacted by the global water crisis today.
From January 15 until April 15 of this year, every purchase of a Stella Artois 12-pack (both bottles and cans, including Stella Artois Cidre) will help Water.org provide 12 months of clean water for one person in the developing world. For those watching the big game at a bar, the purchase of one pint or bottle of Stella Artois will help provide one month of clean water. And as in years past, in 2018 every purchase of a Limited-Edition Stella Artois Chalice will help provide five years of clean water for one person in the developing world.
To view the multimedia release go to:
https://www.multivu.com/players/English/8254751-stella-artois-water-org-super-bowl-party/
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
